Revisit the Practice of Lymph Node Biopsy in Patients Diagnosed as Ductal Carcinoma In Situ Before Operation: A Retrospective Analysis of 682 Cases and Evaluate the Role of Breast MRI

Hung-Wen Lai
Changhua Christian Medical Foundation Changhua Christian Hospital

Yi Lin Chang (✉ klaire_2014@outlook.com)
Changhua Christian Medical Foundation Changhua Christian Hospital

Shou-Tung Chen
Changhua Christian Medical Foundation Changhua Christian Hospital

Yu-Chun Chang
Changhua Christian Medical Foundation Changhua Christian Hospital

Wen-Pei Wu
Changhua Christian Medical Foundation Changhua Christian Hospital

Dar-Ren Chen
Changhua Christian Medical Foundation Changhua Christian Hospital

Shou-Jen Kuo
Changhua Christian Medical Foundation Changhua Christian Hospital

Research Article

Keywords: ductal carcinoma in situ, upgrade, lymph node metastasis, sentinel lymph node biopsy (SLNB), mastectomy

Posted Date: February 23rd, 2021

DOI: https://doi.org/10.21203/rs.3.rs-237060/v1

License: ☇ This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Background:** The optimal axillary lymph node (ALN) management strategy in patients diagnosed with ductal carcinoma in situ (DCIS) preoperatively remains controversial. The value of breast magnetic resonance imaging (MRI) to predict ALN metastasis pre-operative DCIS patients were evaluated.

**Methods:** Patients with primary DCIS with or without pre-operative breast MRI evaluation and underwent breast surgery were recruited from single institution. The value of breast MRI for ALN evaluation, predictors of breast & ALN surgeries, upgrade from DCIS to invasive cancer, and ALN metastasis were analyzed.

**Results:** A total of 682 cases with pre-operative diagnosis of DCIS were enrolled in current study. The rate of upgrade to invasive cancer were found in 34.2% of specimen, and this upgrade rate is 23% for patients received breast conserving surgery and 40.7% for mastectomy (p<0.01). Large pre-operative imaging tumor size and post-operative invasive component were risk factors to ALN metastasis. Breast MRI had 53.8% sensitivity, 77.8% specificity, 14.9% positive predictive value, 95.9% negative predictive value (NPV), and 76.2% accuracy to predict ALN metastasis in pre-OP DCIS patients. In MRI node negative breast cancer patients with MRI tumor size < 3cm, the NPV was 96.4%, and all these false negative cases were N1. Pre-OP diagnosed DCIS patients with MRI tumor size <3 cm and node negative suitable for BCS could safety omit SLNB if whole breast radiotherapy is to be performed.

**Conclusion:** Breast MRI had high NPV to predict ALN metastasis in pre-OP DCIS patients, which is useful and could be provided as shared decision-making reference.

Introduction

Lymph node evaluation plays important role of breast cancer staging and management, and had been evolved from axillary lymph node dissection (ALND) to sentinel lymph node biopsy (SLNB). In theory, ductal carcinoma in situ (DCIS) does not metastasize to adjacent lymph nodes, and axillary lymph node evaluation or surgery had limited role. DCIS as determined by pathologic analysis of biopsy specimens, however, does not preclude invasive disease in excised specimens, and up to 50% (range, 3.5–56%) of core needle biopsy (CNB) or vacuum-assisted core biopsy (VACB) diagnosed DCIS would upgrade to have an invasive component (IC)[1–17]. Indication and adequacy of application of SLNB in lymph node evaluation of patients with pre-operative (pre-OP) DCIS diagnosed by biopsy remained a debated issue as SLNB remains an invasive procedure and not morbidity free[18–20].

In current practice guideline, SLNB was not routinely suggested for patients with pre-OP DCIS planned to receive breast conserving surgery (BCS) as the rate of upgrade to DCIS-IC is not so high in lesion suitable for local excision, and even if invasive component found a secondary SLNB could still be performed[21]. Furthermore, according to ACOSZ0011, even 1–2 positive SLNB could be managed with whole breast radiotherapy in T1-T2 tumor received BCS without ALND[22]. In patients with pre-OP DCIS and indicated for mastectomy, however, SLNB remained recommended as the upgrade rate is increased and there would
be rare chance for secondary lymph node surgical biopsy. In recent studies, the rate of positive SLNB following mastectomy of patients with pre-OP biopsied DCIS was low (around 10%-20%), which raising the question of the need and value of routine SLNB in this particular group of patients in modern era of breast imaging[1, 23–28].

In our previous study we had showed pre-OP breast magnetic resonance image (MRI) had clinical benefit in predict DCIS with invasive component (DCIS-IC). Certain characteristics of breast MRI, like MRI evidence of NAC invasion, mass-like lesions, and measurable apparent diffusion coefficient area were significant predictors of DCIS-IC[29]. DCIS-IC was found to be the most important predictor of ALN metastasis in SLNB in patients with pre-OP DCIS. We hypothesized that pre-OP MRI could have potential role for ALN evaluation and prevent unnecessary SLNB in some conditions.

The aim of current study is to evaluate the role of ALN surgery in pre-OP biopsy diagnosed DCIS patients, and investigate the accuracy of breast MRI to predict ALN metastasis. The rate and predictors of upgrade from pre-OP DCIS to DCIS-IC, ALN metastasis, and potential of breast MRI to replace SLNB in pre-OP biopsy diagnosed DCIS patients would be analyzed and discussed.

**Materials And Methods**

**Patients**

Patients with primary DCIS as diagnosed by biopsy (mainly CNB, VACB or excision biopsy) with or without pre-OP breast MRI evaluation and underwent breast surgery during the period of January 2009 to December 2018 at the Changhua Christian Hospital (CCH), a tertiary medical center in central Taiwan, were retrospectively recruited from the breast cancer database. Patients without detailed clinicopathologic data were excluded (Fig. 1). The study was approved by the institutional review board (IRB) of CCH (CCH IRB No. 140404). The clinicopathologic factors gathered from the data base included age, tumor size, biopsy method, tumor grade, and status of estrogen receptor (ER), progesterone receptor (PR), and human epithelial growth factor receptor 2 (HER-2) expression.

**Definition The Adequacy Of Sentinel Lymph Node Biopsy (slnb):**

In patients whom SLNB was indicated, methylene blue and/or radioisotope (Tc99m) were used. Indication and threshold for surgical lymph biopsy in patients with pre-OP DCIS patients remained a controversial issue. When IC present, SLNB could be viewed as “adequate-treatment” while no axillary surgery seemed likely to “under-treatment”. When pure DCIS found in permanent pathology, SLNB seemed “over-treatment” and patients without surgical lymph node biopsy viewed as “adequate-treatment”. We apply the above mentioned: “adequate-treatment, under-treatment, over-treatment” to our patients according to their post-operative pathology and whether ALN surgery was performed.
To evaluate the indication and adequacy of surgical lymph node biopsy of patients with pre-OP biopsy diagnosed DCIS patients, another group of pre-OP invasive cancer patients were identified for comparison. The risk of final ALN metastasis, the degree of ALN metastasis (N1 (1–3 nodes), N2(4–9 nodes), and N3(> 10 nodes) were compared between different groups of patients, namely pre-OP DCIS, post-OP pure DCIS, DCIS-IC, and invasive cancer patients.

**Predictors for upgrade from DCIS to DCIS with invasive component (DCIS-IC)**

Patients were separated into two groups, namely a DCIS group comprising patients with post-operative (post-OP) histopathologic evidence of pure DCIS and a DCIS-IC group comprising patients with post-OP evidence of DCIS with invasive component (i.e., basement membrane invasion, characterized immunohistochemically by the lack of p63 staining in myoepithelial cells).

**Magnetic Resonance Imaging (mri) And Protocol**

The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), accuracy of breast MRI in prediction of ALN metastasis was evaluated by comparing the concordance of pre-operative breast MRI lymph node report and post-operative pathologic lymph node status. The protocol and method of breast MRI used in current study had been reported before[29], and a brief summary was described. MR imaging was performed with a Siemens MAGNETOM Verio3.0 Tesla MRI machine. All patients were imaged in the prone position with both breasts placed into a dedicated 16-channelbreast coil.

MR imaging protocols included the following: bilateral laxial turbo-spin-echo fat-suppressed T2-weighted imaging (TR/TE4630/70 ms; field of view 320 mm; slice thickness 3 mm; number of excitations 1), axial turbo-spin-echo T1 weighted imaging (TR/TE736/9.1 ms; field of view 320 mm; slice thickness 3 mm; number of excitations 1), and diffusion weighted imaging (DWI) (TR/TE5800/82 ms; field of view 360 mm; slice thickness 3 mm, with b values of 0, 400, and 800 sec/mm2). Dynamic contrast enhanced MR images (DCE-MRI) were obtained with a three-dimensional fat-suppressed volumetric interpolated breath-hold examination (VIBE) sequence with parallel acquisition once before and five times after a bolus injection of gadobenate dimeglumine (0.1 mmol/ kg). Both breasts were examined in the transverse plane at 60 s intervals in each phase of the dynamic studies. All of the MRI readings were interpreted by an experienced, board-certified breast imaging radiologist (HKW), who had a 35-years radiologist career and 15 years’ experience of breast MRI.

**Statistical Analyses**

Data are expressed as mean ± standard deviation for continuous variables. Categorical variables were compared using the chi-square test or Fisher’s exact test when appropriate. The independent t-test was used to compare continuous variables. A P value of less than 0.05 was considered to indicate statistical
significance; all tests were two-tailed. All statistical analyses were performed on a personal computer with the statistical package SPSS for Windows (Version 19.0, SPSS, Chicago).

Results

According to inclusion and exclusion criteria, a total of 682 cases with pre-OP biopsy diagnosed DCIS were enrolled in current study. Among our patients, 252 (37%) received BCS while 430 (63%) received mastectomy, and surgical lymph node biopsy was performed in 90.9% of them. The clinicopathologic characteristics and management flow chart of pre-OP DCIS patients were shown in Table 1 & Fig. 1. Post-OP upgrade to invasive breast cancer were found in 34.2% (233/682) breast cancer specimens, and this upgrade rate is 23% (58/252) for patients received BCS and 40.7% (175/430) mastectomy (Table 2, p < 0.01).
Table 1
Clinical presentations and demographic data of 682 patients with pre-operative diagnosis of ductal carcinoma in situ (DCIS)

| N = 682 | Mean ± SD (%) |
|---------|---------------|
| Age, year | 52.3 ± 10.1 |
| Location |               |
| Right    | 328(48.1)     |
| Left     | 354(51.9)     |
| Biopsy method(N/A = 3) |            |
| CNB      | 421(62)       |
| Stereotactic biopsy | 167(24.6) |
| Excisional biopsy | 88(12.9)   |
| MMG      | 3(0.4)        |
| Tumor size, cm | 2.2 ± 2.5 |
| Lymph node(N/A = 33) |         |
| Positive | 49(7.6)       |
| Negative | 600(92.4)     |
| Stage (N/A = 33) |           |
| 0        | 390(60.1)     |
| I        | 183(28.2)     |
| II       | 65(10.0)      |
| III      | 11(1.7)       |
| Lymph node stage(N/A = 83) |       |
| N0       | 549(91.7)     |
| N1       | 40(6.7)       |
| N2       | 7(1.2)        |
| N3       | 3(0.5)        |
| Grade(N/A = 74) |         |

NA: not available, CNB: core needle biopsy, MMG: mammography guided biopsy, ER: estrogen receptor, PR: progesterone receptor, HER-2: human epithelial receptor type 2, OP: operation, DCIS: ductal carcinoma in situ, LCIS: lobular carcinoma in situ, ILC: infiltrating lobular carcinoma, IDC: infiltrating ductal carcinoma
| N = 682 | Mean ± SD (%) |
|---------|---------------|
| I       | 76(12.5)      |
| II      | 337(55.4)     |
| III     | 195(32.1)     |
| ER (N/A = 24) |          |
| Positive | 484(73.6)    |
| Negative | 174(26.4)    |
| PR (N/A = 33) |          |
| Positive | 438(67.5)    |
| Negative | 211(32.5)    |
| HER-2 (N/A = 203) |    |
| Positive | 178(37.2)    |
| Negative | 301(62.8)    |
| Post-OP Pathology |          |
| DCIS    | 412(60.4)    |

NA: not available, CNB: core needle biopsy, MMG: mammography guided biopsy, ER: estrogen receptor, PR: progesterone receptor, HER-2: human epithelial receptor type 2, OP: operation, DCIS: ductal carcinoma in situ, LCIS: lobular carcinoma in situ, ILC: infiltrating lobular carcinoma, IDC: infiltrating ductal carcinoma
|                          | Mean ± SD (%) |
|--------------------------|---------------|
| LCIS                     | 5(0.7)        |
| DCIS + LCIS              | 7(1.0)        |
| DCIS + microinvasive     | 5(0.7)        |
| DCIS + tubular carcinoma | 1(0.1)        |
| DCIS + mucinous carcinoma| 3(0.4)        |
| IDC + DCIS               | 228(33.4)     |
| IDC                      | 9(1.3)        |
| ILC                      | 1(0.1)        |
| Other                    | 11(1.6)       |

NA: not available, CNB: core needle biopsy, MMG: mammography guided biopsy, ER: estrogen receptor, PR: progesterone receptor, HER-2: human epithelial receptor type 2, OP: operation, DCIS: ductal carcinoma in situ, LCIS: lobular carcinoma in situ, ILC: infiltrating lobular carcinoma, IDC: infiltrating ductal carcinoma
Table 2
Upgrade rate, adequacy of surgical lymph node biopsy, and rate of lymph node metastasis in patients diagnosed as ductal carcinoma in situ before operation.

### Upgrade ratio versus operation method

|                  | BCS | Mastectomy | Total   | P value |
|------------------|-----|------------|---------|---------|
| DCIS             | 194 | 255        | 449(65.8%) | < 0.01  |
| DCIS-IC          | 58  | 175        | 233(34.2%) |         |
| Total            | 252 (37%) | 430 (63%)  | 682     |         |

### Post-OP pathology and lymph node surgery

| Post-OP pathology | DCIS | DCIS-IC | Total   | P value |
|-------------------|------|---------|---------|---------|
| Axillary surgery  |      |         |         |         |
| ALN biopsy/dissection | 397(58.2%) | 223(32.7%) | 620 | 0.01 |
| over treatment    |      |         |         |         |
| adequate treatment|      |         |         |         |
| No axillary surgery | 52(7.6%) | 10(1.5%) | 62     |         |
| adequate treatment|      |         |         |         |
| under-treatment   |      |         |         |         |
| Total             | 449  | 233     | 682(100%) |         |

### Pathology and lymph node metastasis distribution

|                     | Pre-OP DCIS | Pure-DCIS | DCIS-IC | Pre-OP invasive cancer | P value |
|---------------------|-------------|-----------|---------|-------------------------|---------|
| N = 682             | N = 449     | N = 233   | N = 2268|                         |         |
| No LN metastasis    | 92.4% (600/649) | 99.2% (394/397) | 79.4% (177/223) | 61% (1385/2268) | < 0.01 |
| LN metastasis       | 7.6% (49/649) | 0.8% (3/397) | 20.6% (46/223) | 39% (883/2268) |         |
| No axilla surgery   | N = 33      | N = 52    | N = 10  | N = 0                   |         |
| N1                  | 0           | 1 ITC, 1 micro-metastasis | 80.4% (37/46) | 68% (600/883) |         |
| N2                  | 0           | 0         | 15.2% (7/46) | 21.9% (193/883) |         |

DCIS: ductal carcinoma in situ, DCIS-IC: ductal carcinoma in situ with invasive component, BCS: breast conserving surgery, ALN: axillary lymph node, OP: operation, LN: lymph node, ITC: isolated tumor cell
| Upgrade ratio versus operation method |
|--------------------------------------|
| N3                                   |
| 0                                    |
| 1                                    |
| 4.3% (2/46)                          |
| 10.2% (90/883)                       |
| Total                                |
| 419 (100%)                           |
| 230 (100%)                           |

**Breast MRI lymph node metastasis evaluation**

|                         | MRI predict LN metastasis | MRI predict LN negative | Total |
|-------------------------|---------------------------|-------------------------|-------|
| Pathology LN metastasis | 14                        | 12                      | 26    |
| Pathology LN negative   | 80                        | 280                     | 360   |
| Total                   | 94                        | 292                     | 386   |

- Sensitivity = 14/26 = 53.8%
- Specificity = 280/360 = 77.8%
- Positive predictive value (PPV) = 14/94 = 14.9%
- Negative predictive value (NPV) = 280/292 = 95.9%
- Accuracy = (14 + 280) / 386 = 76.2%

DCIS: ductal carcinoma in situ, DCIS-IC: ductal carcinoma in situ with invasive component, BCS: breast conserving surgery, ALN: axillary lymph node, OP: operation, LN: lymph node, ITC: isolated tumor cell

The risk of ALN metastasis rate is overall 7.6% in pre-operative DCIS patients, 0.8% in post-operative pure DCIS, and 20.6% in post-operative DCIS-IC. The rate and distribution of ALN metastases of 682 patients with pre-OP diagnosed DCIS were compared with another cohort of 2268 pre-OP diagnosed invasive cancer patients and summarized in Table 2. According to post-OP pathology and whether SLNB was performed, 32.6% of SLNB was rated as “adequate-treatment”, 58.4% “over-treatment”, and 1.5% patients “under-treatment” while 7.6% patients with post-OP pure DCIS did not receive SLNB (“adequate-management”, Fig. 1 & Table 2).

About 386 with detail pre-OP MRI ALN evaluation and post-OP pathologic report were analyzed for concordance, and MRI had 53.8% sensitivity, 77.8% specificity, 14.9% PPV, 95.9% NPV, and 76.2% overall accuracy (Table 2). In pre-OP MRI evaluated tumor size < 3cm and no sign of ALN node metastasis breast cancer patients, the NPV was 96.4%, and all the 3.6% (5/137) false negative (FN) cases were N1 patients. Among 70 patients received BCS, only 1 patient was found to have lymph node metastasis (N1:1/22). Another 67 patients received mastectomy, 4 patients were found to have lymph node metastasis (all N1: 2/13, 1/5, 1/2, 1/3).
The differences between patients who received breast (BCS versus mastectomy) and lymph node surgeries were compared and shown in Table 3. Larger pre-OP imaging tumor size is an independent risk factor for mastectomy and surgical ALN biopsy. The rate of surgical ALN biopsy rate is 96.3% (414/430) in mastectomy group, and 81.7% (206/252) in BCS (partial mastectomy) group (P < 0.01). OP method was also related to upgrade to DCIS, patients received total mastectomy had higher upgrade rate than partial mastectomy (BCS) patients (40.7% versus 23%, P < 0.01, Table 3).
Table 3
Predictors of patients’ selection for breast conserving surgery, mastectomy, and axillary lymph node surgery

|                      | Total mastectomy versus partial mastectomy (BCS) | Lymph node surgery versus no surgery |
|----------------------|--------------------------------------------------|-------------------------------------|
|                      | Total mastectomy | Partial mastectomy | P value | No LN surgery | With LN surgery | P value |
| Pre-OP DCIS (N = 682) | N = 430          | N = 252             |         | N = 62        | N = 620         |         |
| Age, year            | 51.9 ± 9.9       | 53.1 ± 10.5         | 0.14    | 54 ± 12.2     | 52.2 ± 9.9      | 0.17    |
| Location             | 0.33              | 0.31                |         |               |                 |         |
| Right                | 213(49.5)         | 115(45.6)           | <0.01   | 26(41.9)      | 302(48.7)       | <0.01   |
| Left                 | 217(50.5)         | 137(54.4)           |         | 36(58.1)      | 318(51.3)       |         |
| Biopsy method        | N/A = 3           | N/A = 0             | <0.01   | N/A = 0       | N/A = 3         | <0.01   |
| CNB                  | 298(69.8)         | 123(48.8)           |         | 19(30.6)      | 402(65.2)       |         |
| Stereotactic biopsy  | 84(19.7)          | 83(32.9)            |         | 23(37.1)      | 144(23.3)       |         |
| Excisional biopsy    | 43(10.1)          | 45(17.9)            |         | 18(29)        | 70(11.3)        |         |
| MMG                  | 2(0.5)            | 1(0.4)              |         | 2(3.2)        | 1(0.2)          |         |
| Sonogram Tumor size, cm | 2.2 ± 1.2       | 1.6 ± 0.8           | <0.01   | 1.7 ± 1.4     | 2 ± 1.1         | 0.11    |
| Mammogram Tumor size, cm | 2.9 ± 1.3       | 2.0 ± 0.9           | <0.01   | 1.6 ± 0.4     | 2.6 ± 1.2       | 0.10    |
| MRI Tumor size, cm   | 4.5 ± 2.3         | 2.8 ± 1.4           | <0.01   | 2.7 ± 1.7     | 4 ± 2.2         | <0.01   |
| Pathology Tumor size*, cm (invasive) | 2.6 ± 2.9       | 1.7 ± 1.6           | <0.01   | 1.8 ± 1.7     | 2.3 ± 2.6       | 0.22    |
| Gross Tumor size, cm# (invasive + non-invasive) | 4 ± 2.6          | 2.2 ± 1.4           | <0.01   | 2.6 ± 1.8     | 3.5 ± 2.4       | 0.04    |
| Stage                | N/A = 11          | N/A = 22            | <0.01   | N/A = 12      | N/A = 21        | 0.03    |

*Pathology Tumor size: invasive component tumor size, #Gross Tumor size: invasive + non-invasive component tumor size,

MMG: mammography guided biopsy, LN: lymph node, SLNB: sentinel lymph node biopsy, ALND: axillary lymph node dissection, ND: not done, OP: operation, DCIS: ductal carcinoma in situ, TNBC: triple negative breast cancer, ER: estrogen receptor, PR: progesterone receptor, HER-2: human epithelial grow receptor type 2, N/A: not available
| | Total mastectomy versus partial mastectomy (BCS) | Lymph node surgery versus no surgery |
|---|---|---|
| 0 | 226(53.9) 164(71.3) | 40(80) 350(58.4) |
| I | 130(31) 53(23) | 8(16) 175(29.2) |
| II | 54(12.9) 11(4.8) | 2(4) 63(10.5) |
| III | 9(2.1) 2(0.9) | 0(0) 11(1.8) |
| Grade | N/A = 38 N/A = 36 | < 0.01 N/A = 19 N/A = 55 0.14 |
| I | 39(9.9) 37(17.1) | 6(14.0) 70(12.4) |
| II | 215(54.8) 122(56.5) | 29(67.4) 308(54.5) |
| III | 138(35.2) 57(26.4) | 8(18.6) 187(33.1) |
| ER | N/A = 9 N/A = 15 | < 0.01 N/A = 11 N/A = 13 0.25 |
| Positive | 293(69.6) 191(80.6) | 41(80.4) 443(73.0) |
| Negative | 128(30.4) 46(19.4) | 10(19.6) 164(27.0) |
| PR | N/A = 13 N/A = 20 | < 0.01 N/A = 11 N/A = 22 0.15 |
| Positive | 259(62.1) 179(77.2) | 39(76.5) 399(66.7) |
| Negative | 158(37.9) 53(22.8) | 12(23.5) 199(33.3) |
| HER-2(N/A = 203) | N/A = 121 N/A = 82 | 0.53 N/A = 29 N/A = 174 0.64 |
| Positive | 118(38.2) 60(35.3) | 11(33.3) 167(37.4) |
| Negative | 191(61.8) 110(64.7) | 22(66.7) 279(62.6) |
| Subtype | N/A = 68 N/A = 52 | < 0.01 N/A = 24 N/A = 96 0.17 |
| Luminal A | 198(54.7) 133(66.5) | 27(71.1) 304(58.0) |
| Luminal B1 | 23(6.4) 11(5.5) | 2(5.3) 32(6.1) |
| Luminal B2 | 50(13.8) 32(16.0) | 7(18.4) 75(14.3) |

*Pathology Tumor size: invasive component tumor size, #Gross Tumor size: invasive + non-invasive component tumor size,

MMG: mammography guided biopsy, LN: lymph node, SLNB: sentinel lymph node biopsy, ALND: axillary lymph node dissection, ND: not done, OP: operation, DCIS: ductal carcinoma in situ, TNBC: triple negative breast cancer, ER: estrogen receptor, PR: progesterone receptor, HER-2: human epithelial grow receptor type 2, N/A: not available
|                          | Total mastectomy versus partial mastectomy (BCS) | Lymph node surgery versus no surgery |
|--------------------------|--------------------------------------------------|-------------------------------------|
| HER-2(+)                 | 56(15.5)                                          | 2(5.3)                              |
| TNBC                     | 35(9.7)                                           | 0(0)                                |
| Post-OP pathology        | <0.01                                            | <0.01                               |
| DCIS                     | 255(59.3)                                         | 52(83.9)                            |
| Upgrade                  | 175(40.7)                                         | 10(16.1)                            |
| Ki-67                    | N/A = 313                                         | N/A = 57                            |
| ≤20                      | 67(57.3)                                          | 3(60)                               |
| >20                      | 50(42.7)                                          | 2(40)                               |
| MRI LN metastasis        | NA = 166                                          | NA = 28                             |
| Yes                      | 69(26.1)                                          | 90(24.1)                            |
| No                       | 195(73.9)                                         | 283(75.9)                           |
| Lymph node stage         | N/A = 60                                          | N/A = 15                            |
| N0                       | 327(88.4)                                         | 502(90.9)                           |
| N1                       | 35(9.5)                                           | 40(7.2)                             |
| N2                       | 6(1.6)                                            | 7(1.3)                              |
| N3                       | 2(0.5)                                            | 3(0.5)                              |
| LN Metastasis            | N/A = 8                                           | N/A = 29                            |
| Yes                      | 42(10)                                            | 49(8)                               |
| No                       | 380(90)                                           | 567(92)                             |
| OP method                | -                                                 | -                                   |

*Pathology Tumor size: invasive component tumor size, #Gross Tumor size: invasive + non-invasive component tumor size,

MMG: mammography guided biopsy, LN: lymph node, SLNB: sentinel lymph node biopsy, ALND: axillary lymph node dissection, ND: not done, OP: operation, DCIS: ductal carcinoma in situ, TNBC: triple negative breast cancer, ER: estrogen receptor, PR: progesterone receptor, HER-2: human epithelial grow receptor type 2, N/A: not available
|                          | **Total mastectomy versus partial mastectomy (BCS)** | **Lymph node surgery versus no surgery** |
|--------------------------|-----------------------------------------------------|----------------------------------------|
| Total                    | -                                                   | 16(25.8)                               |
| Partial                  | -                                                   | 46(74.2)                               |
| Method LN                | < 0.01                                             | -                                      |
| SLNB                     | 350(81.4)                                          | 178(70.6)                              |
| SLNB + ALND              | 31(7.2)                                            | 18(7.1)                                |
| ALND                     | 33(7.7)                                            | 10(4)                                  |
| ND                       | 16(3.7)                                            | 46(18.3)                               |

*Pathology Tumor size: invasive component tumor size, #Gross Tumor size: invasive + non-invasive component tumor size,

|                          | **Total mastectomy versus partial mastectomy (BCS)** | **Lymph node surgery versus no surgery** |
|--------------------------|-----------------------------------------------------|----------------------------------------|
|                          |                                                    |                                        |

MMG: mammography guided biopsy, LN: lymph node, SLNB: sentinel lymph node biopsy, ALND: axillary lymph node dissection, ND: not done, OP: operation, DCIS: ductal carcinoma in situ, TNBC: triple negative breast cancer, ER: estrogen receptor, PR: progesterone receptor, HER-2: human epithelial grow receptor type 2, N/A: not available

Predictors for post-OP upgraded to DCIS-IC were shown in Table 4, and larger tumor size, ER and/or PR negative tumors were associated with upgrade to DCIS-IC. Predictors for LN metastasis for patients with pre-OP diagnosed DCIS were evaluated, pre-OP imaging tumor size, DCIS-IC, and MRI predicted lymph node metastasis were risk factors to lymph node metastasis. In multivariate analysis, imaging tumor size (Odds ratio, OR = 1.93), DCIS-IC (OR = 34.9) remained important factors (Table 5).
Table 4
Predictors for upgrade to ductal carcinoma in situ (DCIS) with invasive component (IC) in pre-operative biopsy diagnosed DCIS patients

|                | Post-OP pure DCIS (N = 449) | Post-OP upgrade to DCIS-IC (N = 233) | P value |
|----------------|-----------------------------|-------------------------------------|---------|
| Age, year      | 52 ± 9.8                    | 52.9 ± 10.8                         | 0.29    |
| Location       |                             |                                     | 0.62    |
| Right          | 219(48.8)                   | 109(46.8)                           |         |
| Left           | 230(51.2)                   | 124(53.2)                           |         |
| Biopsy method  |                             |                                     | < 0.01  |
| N/A            | 2                           | 1                                   |         |
| CNB            | 233(52.1)                   | 188(81)                             |         |
| Stereotactic biopsy | 140(31.3)               | 27(11.6)                            |         |
| Excisional biopsy | 71(15.9)                | 17(7.3)                             |         |
| MMG            | 3(0.7)                      | 0(0)                                |         |
| Sonogram Tumor size, cm | 1.9 ± 1.1          | 2.2 ± 1.2                           | < 0.01  |
| Mammogram Tumor size, cm | 2.4 ± 1.3         | 2.8 ± 1.1                           | 0.14    |
| MRI Tumor size, cm | 3.6 ± 2.2               | 4.5 ± 2.1                           | < 0.01  |
| Pathology Tumor size*, cm | 2.7 ± 2.7      | 1.4 ± 1.9                           | < 0.01  |
| Gross Tumor size#, cm | 3.3 ± 2.4            | 3.8 ± 2.4                           | 0.02    |
| Stage (N/A = 33) |                             |                                     | < 0.01  |
| 0              | 381(91.1)                   | 9(3.9)                              |         |
| I              | 26(6.2)                     | 157(68.0)                           |         |
| II             | 10(2.4)                     | 55(23.8)                            |         |
| III            | 1(0.2)                      | 10(4.3)                             |         |
| Grade (N/A = 74) |                             |                                     | < 0.01  |
| N/A            | 44                          | 30                                  |         |

*Pathology Tumor size: invasive component tumor size, #Gross Tumor size: invasive + non-invasive component tumor size,

MMG: mammography guided biopsy, LN: lymph node, SLNB: sentinel lymph node biopsy, ALND: axillary lymph node dissection, ND: not done, OP: operation, DCIS: ductal carcinoma in situ, TNBC: triple negative breast cancer, ER: estrogen receptor, PR: progesterone receptor, HER-2: human epithelial grow receptor type 2, N/A: not available
|                | Post-OP pure DCIS (N = 449) | Post-OP upgrade to DCIS-IC (N = 233) | P value |
|----------------|-----------------------------|-------------------------------------|---------|
| I              | 28(6.9)                     | 48(23.6)                            |         |
| II             | 211(52.1)                   | 126(62.1)                           |         |
| III            | 166(41.0)                   | 29(14.3)                            |         |
| ER             | N/A = 24                    |                                     | < 0.01  |
| Positive       | 335(78.8)                   | 149(63.9)                           |         |
| Negative       | 90(21.2)                    | 84(36.1)                            |         |
| PR (N/A = 33)  | N/A = 33                    |                                     | < 0.01  |
| Positive       | 303(72.8)                   | 135(57.9)                           |         |
| Negative       | 113(27.2)                   | 98(42.1)                            |         |
| HER-2 (N/A = 203) | N/A = 199       | N/A = 4                             | 0.25    |
| Positive       | 99(39.6)                    | 79(34.5)                            |         |
| Negative       | 151(60.4)                   | 150(65.5)                           |         |
| MRI LN metastasis | N/A = 184              | N/A = 91                            | 0.01    |
| Yes            | 50(18.9)                    | 44(31.0)                            |         |
| No             | 215(81.1)                   | 98(69.0)                            |         |
| Lymph node stage | N/A = 61                 | N/A = 22                            | < 0.01  |
| N0             | 385(99.2)                   | 164(77.7)                           |         |
| N1             | 2(0.5)                      | 38(18.0)                            |         |
| N2             | 0(0)                        | 7(3.3)                              |         |
| N3             | 1(0.3)                      | 2(0.9)                              |         |
| OP method      |                             |                                     | < 0.01  |
| Total          | 255(56.8)                   | 175(75.1)                           |         |
| Partial        | 194(43.2)                   | 58(24.9)                            |         |

*Pathology Tumor size: invasive component tumor size, *Gross Tumor size: invasive + non-invasive component tumor size,

MMG: mammography guided biopsy, LN: lymph node, SLNB: sentinel lymph node biopsy, ALND: axillary lymph node dissection, ND: not done, OP: operation, DCIS: ductal carcinoma in situ, TNBC: triple negative breast cancer, ER: estrogen receptor, PR: progesterone receptor, HER-2: human epithelial grow receptor type 2, N/A: not available
| N = 682 | Post-OP pure DCIS (N = 449) | Post-OP upgrade to DCIS-IC (N = 233) | P value |
|---------|----------------------------|------------------------------------|---------|
| LN Meta | N/A = 30                   | N/A = 3                            | < 0.01  |
| Yes     | 3(0.7)                     | 46(20.0)                           |         |
| No      | 416(99.3)                  | 184(80.0)                          |         |
| Method_LN|                           |                                    | < 0.01  |
| SLNB    | 365(81.3)                  | 163(70.0)                          |         |
| SLNB + ALND | 14(3.1)       | 35(15.0)                           |         |
| ALND    | 18(4.0)                    | 25(10.7)                           |         |
| ND      | 52(11.6)                   | 10(4.3)                            |         |

*Pathology Tumor size: invasive component tumor size, #Gross Tumor size: invasive + non-invasive component tumor size,

MMG: mammography guided biopsy, LN: lymph node, SLNB: sentinel lymph node biopsy, ALND: axillary lymph node dissection, ND: not done, OP: operation, DCIS: ductal carcinoma in situ, TNBC: triple negative breast cancer, ER: estrogen receptor, PR: progesterone receptor, HER-2: human epithelial grow receptor type 2, N/A: not available
|                              | Univariate Analysis |       |       |       | Multivariate Analysis |       |       |
|------------------------------|---------------------|-------|-------|-------|-----------------------|-------|-------|
|                              | Odds Ratio | 95% CI | P     | Odds Ratio | 95% CI | P     |
| Age                          | 0.97      | 0.94-1 | 0.06  |           |         |       |
| pathology tumor size         | 1.01      | 0.9–1.13 | 0.9   |           |         |       |
| (invasive, cm)               |           |         |       |           |         |       |
| Pathology tumor size         | 1.32      | 1.1–1.59 | < 0.01 |           |         |       |
| (invasive, cm)               |           |         |       |           |         |       |
| MRI tumor size               | 1.21      | 1.1–1.42 | 0.02  |           |         |       |
| (invasive, cm)               |           |         |       |           |         |       |
| Sonogram tumor size          | 1.8       | 1.4–2.3 | < 0.01 | 1.93      | 1.23–3.03 | < 0.01 |
| (invasive, cm)               |           |         |       |           |         |       |
| Mammogram tumor size         | 1.78      | 1.3–3.09 | 0.04  |           |         |       |
| (invasive, cm)               |           |         |       |           |         |       |
| Pathology tumor size         | 1.03      | 0.91–1.16 | 0.63  |           |         |       |
| (invasive, cm)               |           |         |       |           |         |       |
| Pathology IDC tumor size     | 0.99      | 0.86–1.13 | 0.86  |           |         |       |
| (invasive, cm)               |           |         |       |           |         |       |
| Pathology DCIS tumor size    | 0.54      | 0.15–1.99 | 0.36  |           |         |       |
| (invasive, cm)               |           |         |       |           |         |       |
| Post OP biopsy (IDC) VS DCIS | 34.94     | 10.73–113.79 | < 0.01 | 36.37     | 4.63–288.81 | < 0.01 |
| Grade (II, III) VS I         | 1.1       | 0.42–2.88 | 0.85  |           |         |       |
| ER (positive) VS negative    | 0.61      | 0.33–1.11 | 0.1   |           |         |       |
| PR (positive) VS negative    | 0.7       | 0.38–1.26 | 0.23  |           |         |       |

*Pathology Tumor size: invasive component tumor size, #Gross Tumor size: invasive + non-invasive component tumor size,

MMG: mammography guided biopsy, LN: lymph node, SLNB: sentinel lymph node biopsy, ALND: axillary lymph node dissection, ND: not done, OP: operation, DCIS: ductal carcinoma in situ, TNBC: triple negative breast cancer, ER: estrogen receptor, PR: progesterone receptor, HER-2: human epithelial grow receptor type 2, N/A: not available
Univariate Analysis | Multivariate Analysis
--- | ---
**Odds Ratio | 95% CI | P | Odds Ratio | 95% CI | P**
HER-2 (positive) VS negative | 0.89 | 0.47–1.68 | 0.72 |  
Ki -67 (>20) VS ≤ 20 | 1.64 | 0.71–3.81 | 0.25 |  
MRI lymph node metastasis (Y)VS N | 4.08 | 1.82–9.18 | <0.01 | 2.2 | 0.83–5.83 | 0.11 |

*Pathology Tumor size: invasive component tumor size, #Gross Tumor size: invasive + non-invasive component tumor size,

MMG: mammography guided biopsy, LN: lymph node, SLNB: sentinel lymph node biopsy, ALND: axillary lymph node dissection, ND: not done, OP: operation, DCIS: ductal carcinoma in situ, TNBC: triple negative breast cancer, ER: estrogen receptor, PR: progesterone receptor, HER-2: human epithelial growth receptor type 2, N/A: not available

**Discussion**

In the current study, we enrolled 682 pre-OP DCIS patients and compared ALN metastasis pattern with another cohort of 2268 pre-OP diagnosed invasive cancer. We found 34.2% of these pre-OP DCIS patients upgraded to DCIS-IC in nal pathology, and this upgrade rate was consistent with literate reported range (3.5–56%) [1–17]. The risk of ALN metastasis rate varied widely depends on the pre-operative pathology, and in our current study, the ALN metastasis rate is 7.6% in pre-OP DCIS patients, and up to 39% in pre-OP invasive cancer group (Table 2). In patients with post-OP pure DCIS, the LN metastasis rate is lowest (0.8%), and ALN metastasis was found in 20.6% of patients with DCIS-IC. We also demonstrated that the ALN disease burden (N1-3) varied among different categories of patients (Table 2). These data reminded us the differences of ALN metastatic risk in each category of patients, and more tailored or individualized ALN evaluation strategy should be offered.

Indication and threshold for surgical lymph biopsy in patients with pre-OP biopsy diagnosed DCIS remained a controversy issue for decades. When invasive component present, SLNB was viewed as “adequate-treatment” while no axillary surgery seemed likely to “under-treatment”. When pure DCIS found in permanent pathology, SLNB seemed “over-treatment”. Under this concept, in our pre-OP DCIS patients, 32.6% were adequate-treated with SLNB, 58.4% over-treated, and 1.5% under-treated. Another 7.6% patients with post-OP pure DCIS did not receive surgical axillary biopsy, which should view as adequate-observation. If only “invasive component” present in final pathology viewed as an indication for SLNB, then up to 60% of patients diagnosed with pre-OP DCIS received inadequate axillary management (Table 2). This highlights the “unmet medical need” in modern era of personalized breast cancer care, which over-treated the low risk and/or low disease burden axilla.
In post-OP pure DCIS patients, 0.8% ALN metastasis rate is not justified for surgical ALN biopsy. In pre-OP invasive cancer patients, ALN metastasis rate could up to 39% and surgical lymph node biopsy with either SLN and/or ALND is indicated (Table 2). The group of patients, who diagnosed initially as DCIS, had a substantial risk of upgrade to invasive cancer (34.2% in current study) and 7.6% overall lymph node metastasis cases detected. In patients of DCIS-IC, the ALN metastasis rate up to 20.6%. One could speculate that patients with biopsy proven pre-OP DCIS present a category of “low” (pure DCIS) to “intermediate” (DCIS-IC) risk of ALN metastasis, which possessed some controversy whether routine lymph node surgery should be performed and it remained unsolved issue even in current modern breast imaging era.

According to NCCN and other practice guideline, patients with pre-OP biopsy diagnosed DCIS, selected for BCS and adjuvant radiotherapy, do not routinely indicate for SLNB[30]. As most patients (77% in current study) with pre-OP biopsy diagnosed DCIS received BCS would remain pure DCIS in final pathology report (Fig. 1, Table 2). Furthermore, according to ACOSZ0011 trial, even 1–2 positive sentinel lymph node present, patients could omit ALND if breast cancer with tumor size T1-T2, received BCS and whole breast radiotherapy would be performed[22]. These reasons supported that SLNB is not routinely needed in pre-OP biopsy diagnosed DCIS patients indicated for BCS (Table 2).

However, some patients with pre-OP biopsy diagnosed DCIS and indicated for BCS would have post-op upgrade to DCIS-IC and with more than 2 lymph nodes metastases. In current study, we observed 7 pre-OP DCIS patients who received BCS presented with ALN metastases in final pathology check-up. Five of them were N1, 1 was N2, and the other 1 was N3 status (Fig. 1). This accounts that about 2.7% (7/252) of pre-OP DCIS and indicated BCS patients would have ALN metastasis. Although only few patients would have > 2 occult metastatic lymph nodes, routinely abandon SLNB is also worrisome.

Controversy did persist about the role of SLNB in patients with pre-OP biopsy diagnosed DCIS and indicated for mastectomy. Parallel with increasing early detection of breast cancer, DCIS rate increased up to 14% -20%, and around half (68% in current study) of them would receive mastectomy. This group of patients constituted about 5% of annual breast cancer cases, which constituted a non-ignorable minority[6]. Current practice guideline had suggested SLNB to be performed in pre-OP biopsy diagnosed DCIS and received mastectomy as secondary lymph node staging surgery seems unreliable when post-OP pathology upgrade to invasive breast cancer[31, 32].

In our 430 patients with pre-OP biopsy diagnosed DCIS received mastectomy, 59.3% remained DCIS-post-OP, and in these patients SLNB seemed unnecessary or “over-treatment“. About 40.7%(175/430) of patients with pre-OP DCIS received mastectomy and upgrade to DCIS-IC post-OP. Among these 175 patients, 171 (98%) received SLNB, and 40 (23.5%) was found to have LN metastasis. This accounts for 9.8% (42/430) of pre-OP biopsy diagnosed DCIS and indicated mastectomy patients would have ALN metastasis. This result is consisted with Price et al.’s study, which showed about 10% patients would have ≥ 1 LN metastasis when SLNB was performed in patients with pre-OP biopsy diagnosed DCIS and indicated for mastectomy[6].
The reason that mastectomy patients tend to receive SLNB is that the upgrade rate is higher in patients received total mastectomy than partial mastectomy (BCS) (40.7% versus 23%, P < 0.01, Table 2). This is related to more multicentric breast cancer, more larger tumor size of patients would receive mastectomy than BCS, and larger tumor or multicentric lesions would possess higher risk lead to upgrade to DCIS-IC. Among the predictors of ALN metastasis for patients received SLNB, patients with post-OP invasive component was the highest risk of lymph node metastasis (Table 5).

In current study, we tried to evaluate the pre-operative MRI for pre-OP DCIS patients, and we had 386 patients with detail ALN evaluation and post-operative pathologic report were analyzed for concordance. The accuracy of MRI: sensitivity 53.8%, specificity 77.8%, PPV 14.9%, NPV 95.9%, accuracy 76.2%. This high NPV rate is very useful, especial for patients selected for BCS patients. In patients with MRI estimated tumor size < 3cm & lymph node negative cases, the NPV of ALN metastasis is high (up to 96.4%), and all (3.6%, 5/137) the FN cases were limited to N1 (with 1–2 positive nodes only). Our data supported that pre-OP MRI evaluated node negative patients suitable for BCS patients could safely omitted SLNB if whole breast radiotherapy is to be performed. In mastectomy patients, this high NPV could be used as shared decision making, however, could not guarantee metastatic free lymph node to omit SLNB (Table 2).

Our current study is limited in its retrospective study and limited cases, which could not answer whether subgroup of patients could omit axillary surgery in pre-OP DCIS patients indicated for mastectomy. Our current study, however, did collect of 682 pre-OP DCIS patients with detailed pre-op and post-OP lymph node pathologic report. Of special note that we had 386 patients with detailed pre-OP breast MRI evaluation and post-operative pathologic results, which enable us to evaluate the role of breast MRI in decision of lymph node surgery.

**Conclusion**

Individualized lymph node evaluation/biopsy of pre-OP DCIS patients is warranted due to inherent specimen biopsy error, which lead to substantial upgrade to invasive component found in final pathology, and therefore raise the concern of axillary lymph node metastasis. Patients indicated for mastectomy deserved a more tailored planning as 50% SLNB was not necessary, 40% for staging purpose, and around 10% therapeutic. Pre-OP diagnosed DCIS patients with MRI tumor size < 3cm and node negative condition suitable for BCS could safety omitted SLNB if whole breast radiotherapy is to be performed.

**Abbreviations**

ALN  
axillary lymph node  
DCIS  
ductal carcinoma in situ  
MRI
Declarations

Author Disclosures

None of the authors have conflicts of interest or financial ties to disclose.

Financial Disclosure

Funding: This study was funded by the Ministry of Science and Technology of Taiwan, and the number of this funding was: MOST 108-2314-B-371-006-. This study was also sponsored by research funding provided by the Changhua Christian Hospital 106-CCH-IRP-014, 106-CCH-IRP-015, 107-CCH-HCR-035, and 108-CCH-IRP-122.

Acknowledgement

The authors would like thank Shu-Hsin Pai, Yi-Ru Ke, Chin-Mei Tai, Yun-Ting Chang, Jia-Dan Hsu, and Ying-Ru Lai for the assistance in this study.

References

References:
1. Heymans C, van Bastelaar J, Visschers RGJ, Vissers YLJ: Sentinel Node Procedure Obsolete in Lumpectomy for Ductal Carcinoma In Situ. Clin Breast Cancer 2017, 17:e87-e93.
2. Caswell-Smith P, Wall M: Ductal carcinoma in situ: Is core needle biopsy ever enough? *J Med Imaging Radiat Oncol* 2017, 61:29–33.

3. Podoll MB, Reisenbichler ES, Roland L, Bruner A, Mizuguchi S, Sanders MAG: Feasibility of the Less Is More Approach in Treating Low-Risk Ductal Carcinoma In Situ Diagnosed on Core Needle Biopsy: Ten-Year Review of Ductal Carcinoma In Situ Upgraded to Invasion at Surgery. *Arch Pathol Lab Med* 2018, 142:1120–1126.

4. Munck F, Clausen EW, Balslev E, Kroman N, Tvedskov TF, Holm-Rasmussen EV: Multicentre study of the risk of invasive cancer and use of sentinel node biopsy in women with a preoperative diagnosis of ductal carcinoma in situ. *Br J Surg* 2020, 107:96–102.

5. Prendeville S, Ryan C, Feeley L, O’Connell F, Browne TJ, O’Sullivan MJ, Bennett MW: Sentinel lymph node biopsy is not warranted following a core needle biopsy diagnosis of ductal carcinoma in situ (DCIS) of the breast. *Breast* 2015, 24:197–200.

6. Price A, Schnabel F, Chun J, Kaplowitz E, Goodgal J, Guth A, Axlerod D, Shapiro R, Mema E, Moy L, et al: Sentinel lymph node positivity in patients undergoing mastectomies for ductal carcinoma in situ (DCIS). *Breast J* 2020, 26:931–936.

7. Goyal A, Douglas-Jones A, Monypenny I, Sweetland H, Stevens G, Mansel RE: Is there a role of sentinel lymph node biopsy in ductal carcinoma in situ?: analysis of 587 cases. *Breast Cancer Res Treat* 2006, 98:311–314.

8. Yen TW, Hunt KK, Ross MI, Mirza NQ, Babiera GV, Meric-Bernstam F, Singletary SE, Symmans WF, Giordano SH, Feig BW, et al: Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. *J Am Coll Surg* 2005, 200:516–526.

9. Shin YJ, Kim SM, Yun B, Jang M, Kim B, Lee SH: Predictors of Invasive Breast Cancer in Patients With Ductal Carcinoma In Situ in Ultrasound-Guided Core Needle Biopsy. *J Ultrasound Med* 2019, 38:481–488.

10. Nakhlis F, Harrison BT, Giess CS, Lester SC, Hughes KS, Coopey SB, King TA: Evaluating the Rate of Upgrade to Invasive Breast Cancer and/or Ductal Carcinoma In Situ Following a Core Biopsy Diagnosis of Non-classic Lobular Carcinoma In Situ. *Ann Surg Oncol* 2019, 26:55–61.

11. Lamb LR, Lehman CD, Oseni TO, Bahl M: Ductal Carcinoma In Situ (DCIS) at Breast MRI: Predictors of Upgrade to Invasive Carcinoma. *Acad Radiol* 2019.

12. Lamb LR, Kim G, Oseni TO, Bahl M: Noncalcified Ductal Carcinoma In Situ (DCIS): Rate and Predictors of Upgrade to Invasive Carcinoma. *Acad Radiol* 2020.

13. Sim YT, Litherland J, Lindsay E, Hendry P, Brauer K, Dobson H, Cordiner C, Gagliardi T, Smart L: Upgrade of ductal carcinoma in situ on core biopsies to invasive disease at final surgery: a retrospective review across the Scottish Breast Screening Programme. *Clin Radiol* 2015, 70:502–506.

14. Chin-Lenn L, Mack LA, Temple W, Cherniak W, Quinn RR, Ravani P, Lewin AM, Quan ML: Predictors of treatment with mastectomy, use of sentinel lymph node biopsy and upstaging to invasive cancer in
patients diagnosed with breast ductal carcinoma in situ (DCIS) on core biopsy. *Ann Surg Oncol* 2014, 21:66–73.

15. Sorrentino L, Sartani A, Bossi D, Amadori R, Nebuloni M, Truffi M, Bonzini M, Riggio E, Foschi D, Corsi F: Sentinel node biopsy in ductal carcinoma in situ of the breast: Never justified? *Breast J* 2018, 24:325–333.

16. Watanabe Y, Anan K, Saimura M, Koga K, Fujino M, Mine M, Tamiya S, Nishihara K, Nakano T, Mitsuyama S: Upstaging to invasive ductal carcinoma after mastectomy for ductal carcinoma in situ: predictive factors and role of sentinel lymph node biopsy. *Breast Cancer* 2018, 25:663–670.

17. Allen A, Cauthen A, Dale P, Jean-Louis C, Lord A, Smith B: Evaluating the frequency of upgrade to malignancy following surgical excision of high-risk breast lesions and ductal carcinoma in situ identified by core needle biopsy. *Breast J* 2019, 25:103–106.

18. Verbelen H, Tjalma W, Meirte J, Gebruers N: Long-term morbidity after a negative sentinel node in breast cancer patients. *Eur J Cancer Care (Engl)* 2019, 28:e13077.

19. Verbelen H, Gebruers N, Eeckhout FM, Verlinden K, Tjalma W: Shoulder and arm morbidity in sentinel node-negative breast cancer patients: a systematic review. *Breast Cancer Res Treat* 2014, 144:21–31.

20. De Groef A, Van Kampen M, Tieto E, Schonweger P, Christiaens MR, Neven P, Geraerts I, Gebruers N, Devoogdt N: Arm lymphoedema and upper limb impairments in sentinel node-negative breast cancer patients: A one year follow-up study. *Breast* 2016, 29:102–108.

21. Edge SB, Sheldon DG: Counterpoint: Sentinel Lymph Node Biopsy Is Not Indicated for Ductal Carcinoma In Situ. 2003, 1:207.

22. Giuliani AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, Ollila DW, Hansen NM, Whitworth PW, Blumencranz PW, et al: Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. *JAMA* 2017, 318:918–926.

23. van Roozendaal LM, Goorts B, Klinkert M, Keymeulen K, De Vries B, Strobbe LJA, Wauters CAP, van Riet YE, Degreif E, Rutgers EJT, et al: Sentinel lymph node biopsy can be omitted in DCIS patients treated with breast conserving therapy. *Breast Cancer Res Treat* 2016, 156:517–525.

24. Sakr R, Barranger E, Antoine M, Prugnolle H, Darai E, Uzan S: Ductal carcinoma in situ: value of sentinel lymph node biopsy. *J Surg Oncol* 2006, 94:426–430.

25. Bertozzi S, Cedolini C, Londero AP, Baita B, Giacomuzzi F, Capobianco D, Tortelli M, Uzzau A, Mariuzzi L, Risaliti A: Sentinel lymph node biopsy in patients affected by breast ductal carcinoma in situ with and without microinvasion: Retrospective observational study. *Medicine (Baltimore)* 2019, 98:e13831.

26. Hotton J, Salleron J, Rauch P, Buhler J, Pierret M, Baumard F, Leufflen L, Marchal F: Predictive factors of axillary positive sentinel lymph node biopsy in extended ductal carcinoma in situ treated by simple mastectomy at once. *J Gynecol Obstet Hum Reprod* 2020, 49:101641.

27. Magnoni F, Massari G, Santomauro G, Bagnardi V, Pagan E, Peruzzotti G, Galimberti V, Veronesi P, Sacchini VS: Sentinel lymph node biopsy in microinvasive ductal carcinoma in situ. *Br J Surg* 2019,
106:375–383.

28. Holm-Rasmussen EV, Jensen MB, Balslev E, Kroman N, Tvedskov TF: Risk factors of sentinel and non-sentinel lymph node metastases in patients with ductal carcinoma in situ of the breast: A nationwide study. *Breast* 2018, 42:128–132.

29. Lee CW, Wu HK, Lai HW, Wu WP, Chen ST, Chen DR, Chen CJ, Kuo SJ: Preoperative clinicopathologic factors and breast magnetic resonance imaging features can predict ductal carcinoma in situ with invasive components. *Eur J Radiol* 2016, 85:780–789.

30. Lyman GH, Somerfield MR, Bosserman LD, Perkins CL, Weaver DL, Giuliano AE: Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. *J Clin Oncol* 2017, 35:561–564.

31. Cody HS, Zee KJV: Point: Sentinel Lymph Node Biopsy Is Indicated for Patients With DCIS. 2003, 1:199.

32. Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, Zackrisson S, Senkus E, clinicalguidelines@esmo.org EGCEa: Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.dagger. *Ann Oncol* 2019, 30:1194–1220.

**Figures**

**Figure 1**

Flow chart of patients management of 682 pre-operative biopsy diagnosed ductal carcinoma in situ cases. The number of patients allocation to either breast conserving surgery (BCS) or mastectomy, whether received axillary lymph node surgery, pathology upgrade to invasive component or not, and post-operative lymph node status were described in details.